Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Veesler

Showing results (181-190 of 226) with videos related to

Pageof 23
Sort By:
Science Translational Medicine|May 10, 2023
Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccineYupeng Feng, Meng Yuan, John M Powers, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 10, 2025
Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trialJoon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
Biorxiv : the Preprint Server for Biology|December 10, 2020
Designed proteins assemble antibodies into modular nanocagesRobby Divine, Ha V Dang, George Ueda, et al.
Science (New York, N.Y.)|July 20, 2022
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodiesJun Siong Low, Josipa Jerak, M Alejandra Tortorici, et al.
Science (New York, N.Y.)|April 2, 2021
Designed proteins assemble antibodies into modular nanocagesRobby Divine, Ha V Dang, George Ueda, et al.
Cell Reports|August 21, 2022
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and miceAlexandra C Walls, Laura A VanBlargan, Kai Wu, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccinesAmin Addetia, Alexandra Schäfer, Kaitlin Sprouse, et al.
Science (New York, N.Y.)|July 20, 2022
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccinesJohn E Bowen, Amin Addetia, Ha V Dang, et al.
Biorxiv : the Preprint Server for Biology|April 6, 2021
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Matthew McCallum, Jessica Bassi, Anna De Marco, et al.
Eclinicalmedicine|July 26, 2022
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trialJoon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
Pageof 23

Showing results (181-190 of 226) with videos related to

Sort By:
Pageof 23
Science Translational Medicine|May 10, 2023
Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccineYupeng Feng, Meng Yuan, John M Powers, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 10, 2025
Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trialJoon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
Biorxiv : the Preprint Server for Biology|December 10, 2020
Designed proteins assemble antibodies into modular nanocagesRobby Divine, Ha V Dang, George Ueda, et al.
Science (New York, N.Y.)|July 20, 2022
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodiesJun Siong Low, Josipa Jerak, M Alejandra Tortorici, et al.
Science (New York, N.Y.)|April 2, 2021
Designed proteins assemble antibodies into modular nanocagesRobby Divine, Ha V Dang, George Ueda, et al.
Cell Reports|August 21, 2022
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and miceAlexandra C Walls, Laura A VanBlargan, Kai Wu, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccinesAmin Addetia, Alexandra Schäfer, Kaitlin Sprouse, et al.
Science (New York, N.Y.)|July 20, 2022
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccinesJohn E Bowen, Amin Addetia, Ha V Dang, et al.
Biorxiv : the Preprint Server for Biology|April 6, 2021
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Matthew McCallum, Jessica Bassi, Anna De Marco, et al.
Eclinicalmedicine|July 26, 2022
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trialJoon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
Pageof 23